ZyVersa Therapeutics (ZVSA) Competitors $1.13 -0.01 (-0.88%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends ZVSA vs. BCDA, CELZ, GHSI, FRTX, CNSP, BFRI, KTTA, SNOA, THAR, and CPHIShould you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include BioCardia (BCDA), Creative Medical Technology (CELZ), Guardion Health Sciences (GHSI), Fresh Tracks Therapeutics (FRTX), CNS Pharmaceuticals (CNSP), Biofrontera (BFRI), Pasithea Therapeutics (KTTA), Sonoma Pharmaceuticals (SNOA), Tharimmune (THAR), and China Pharma (CPHI). These companies are all part of the "pharmaceutical products" industry. ZyVersa Therapeutics vs. BioCardia Creative Medical Technology Guardion Health Sciences Fresh Tracks Therapeutics CNS Pharmaceuticals Biofrontera Pasithea Therapeutics Sonoma Pharmaceuticals Tharimmune China Pharma ZyVersa Therapeutics (NASDAQ:ZVSA) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings. Which has higher valuation and earnings, ZVSA or BCDA? BioCardia has higher revenue and earnings than ZyVersa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZyVersa TherapeuticsN/AN/A-$98.30MN/AN/ABioCardia$71K145.91-$11.57M-$4.19-0.54 Do institutionals and insiders believe in ZVSA or BCDA? 3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 0.6% of ZyVersa Therapeutics shares are held by company insiders. Comparatively, 20.0% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer ZVSA or BCDA? BioCardia received 12 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 57.69% of users gave BioCardia an outperform vote. CompanyUnderperformOutperformZyVersa TherapeuticsOutperform Votes3100.00% Underperform VotesNo VotesBioCardiaOutperform Votes1557.69% Underperform Votes1142.31% Does the media favor ZVSA or BCDA? In the previous week, BioCardia had 4 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 6 mentions for BioCardia and 2 mentions for ZyVersa Therapeutics. BioCardia's average media sentiment score of 1.11 beat ZyVersa Therapeutics' score of 0.28 indicating that BioCardia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZyVersa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCardia 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ZVSA or BCDA? ZyVersa Therapeutics currently has a consensus price target of $120.00, indicating a potential upside of 10,519.47%. BioCardia has a consensus price target of $25.00, indicating a potential upside of 1,006.19%. Given ZyVersa Therapeutics' higher possible upside, equities research analysts plainly believe ZyVersa Therapeutics is more favorable than BioCardia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, ZVSA or BCDA? ZyVersa Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Is ZVSA or BCDA more profitable? ZyVersa Therapeutics has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. BioCardia's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ZyVersa TherapeuticsN/A -224.85% -103.22% BioCardia -1,999.77%N/A -208.38% SummaryBioCardia beats ZyVersa Therapeutics on 9 of the 13 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVSA vs. The Competition Export to ExcelMetricZyVersa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.64M$6.56B$5.23B$8.84BDividend YieldN/A8.13%5.54%4.08%P/E RatioN/A10.4094.1017.64Price / SalesN/A355.751,238.8890.90Price / CashN/A53.8241.4336.93Price / Book0.3810.597.236.54Net Income-$98.30M$153.02M$119.93M$226.15M7 Day Performance4.63%3.96%2.14%3.77%1 Month Performance-45.41%-6.72%-2.23%4.46%1 Year Performance-96.08%30.92%32.63%27.57% ZyVersa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVSAZyVersa Therapeutics2.2132 of 5 stars$1.13-0.9%$120.00+10,519.5%-96.1%$2.64MN/A0.002BCDABioCardia3.1323 of 5 stars$2.14+7.0%$25.00+1,071.0%-76.8%$4.53M$480,000.00-0.5116Positive NewsCELZCreative Medical Technology1.6538 of 5 stars$2.55flatN/A-42.0%$4.46M$11,000.00-0.675GHSIGuardion Health SciencesN/A$3.22-2.1%N/A-47.0%$4.35M$12.25M0.6610Gap DownFRTXFresh Tracks TherapeuticsN/A$0.72flatN/A-7.0%$4.27M$8.01M-0.5120News CoverageCNSPCNS Pharmaceuticals1.6108 of 5 stars$0.13flat$0.50+292.8%-99.9%$4.26MN/A0.005Gap UpHigh Trading VolumeBFRIBiofrontera2.2209 of 5 stars$0.76-2.6%$7.00+822.3%-73.0%$4.21M$34.07M-0.3570News CoverageGap DownKTTAPasithea Therapeutics1.2724 of 5 stars$3.18-0.3%N/A-48.3%$4.04M$20,000.000.003News CoverageGap DownSNOASonoma Pharmaceuticals1.3808 of 5 stars$2.91+2.5%N/A+1,530.4%$3.90M$12.73M-0.58180News CoverageTHARTharimmune0.3788 of 5 stars$2.61+4.4%N/A-94.3%$3.89MN/A0.002Gap DownCPHIChina PharmaN/A$0.20+5.3%N/A-59.4%$3.83M$7.01M0.00231Analyst ForecastNews Coverage Related Companies and Tools Related Companies BCDA Alternatives CELZ Alternatives GHSI Alternatives FRTX Alternatives CNSP Alternatives BFRI Alternatives KTTA Alternatives SNOA Alternatives THAR Alternatives CPHI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ZVSA) was last updated on 11/24/2024 by MarketBeat.com Staff From Our Partners[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
